Company Dossier · Health Care
UnitedHealth Group
- S&P 500
- S&P 100
- Dow 30
- Russell 1000
What UnitedHealth Group is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $450 billion, up 6.5% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $23.6 billion, down 6.5% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $3.40 billion, down 7.9% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $5.55 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $2.97 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (October 13, 2026): sentiment 0.40 on a −1 to +1 scale (mixed), confidence 0.60 of 1.Palanor Discourse
- Guidance in the last 90 days: 2 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed March 2, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $0.7 million on the open market.SEC Form 4
- 3,399 institutional managers reported a position at June 30, 2026 (+345 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 174 (227 a year earlier).U.S. Department of Labor (OFLC)
- Headlines in the last 30 days: 7, of which 2 read positive and 1 negative.Palanor headline tone
Company Posture
How Company Posture is measured →What UnitedHealth Group is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending15th pct
- Debt raised—
- Buybacks vs capex97th pct
- Hiring filings5th pct
- Deals and private raises49th pct
- Patent publications81st pct
Confident ↔ Hedging
Mixed
- Call sentiment51st pct
- Call confidence18th pct
- Guidance changes70th pct
- Risk factors added23rd pct
- Insider open-market trades33rd pct
- − Call confidence
- + Guidance changes
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver39th pct
- Stress filings43rd pct
Credit
How these are built →UnitedHealth Group's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$73.3B
- Due within a year $3.8B
- Longer term $69.5B
- Default point $38.6B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Jun 17, 2025 | $1B | 5.300% | 2035 (10y) | +92bp | 5.317% |
| Jun 17, 2025 | $500M | 4.400% | 2028 (3y) | +52bp | 4.417% |
| Jun 17, 2025 | $750M | 4.650% | 2031 (6y) | +70bp | 4.689% |
| Jun 17, 2025 | $750M | 5.950% | 2055 (30y) | +112bp | 6.023% |
| Jul 23, 2024 | $1.5B | 5.500% | 2044 (20y) | +100bp | 5.577% |
| Jul 23, 2024 | $500M | SOFR + 50bp | 2026 (2y) | +35bp | 4.841% |
| Jul 23, 2024 | $1.25B | 4.800% | 2030 (5y) | +65bp | 4.813% |
| Jul 23, 2024 | $1.5B | 4.950% | 2032 (7y) | +80bp | 4.987% |
| Jul 23, 2024 | $2B | 5.150% | 2034 (10y) | +90bp | 5.151% |
| Jul 23, 2024 | $2.75B | 5.625% | 2054 (30y) | +115bp | 5.639% |
| Jul 23, 2024 | $1.85B | 5.750% | 2064 (40y) | +130bp | 5.789% |
| Mar 19, 2024 | $1B | 4.900% | 2031 (7y) | +70bp | 5.018% |
From the pricing term sheets UnitedHealth Group filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
News
UnitedHealth Group: headline tone
Net share of positive headlines, trailing 28 days, −1 to +1
In the news
Headlines that name UnitedHealth Group, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralDoes UnitedHealth (UNH) Present a Case for Patience in a Margin-Repair Story?
insidermonkey.com · via Marketaux · Oct 9, 2026
- PositiveUnitedHealth: A Beat Is Priced In, But There's Room For Surprise (NYSE:UNH)
seekingalpha.com · via Marketaux · Oct 9, 2026
- NeutralUnitedHealth's Recovery Has One Weak Spot (NYSE:UNH)
seekingalpha.com · via Marketaux · Oct 7, 2026
- Negative
- NeutralUnitedHealth Group (UNH) Shows Dividend Strength Amid Solid Q2 Results and Positive Outlook
gurufocus.com · via Marketaux · Sep 30, 2026
- PositiveUnitedHealth: The Recovery Is Working, The Stock Isn't (NYSE:UNH)
seekingalpha.com · via Marketaux · Sep 30, 2026
- Neutral
- Neutral
- Neutral
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (THEGROUP DC, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (UNITEDHEALTH GROUP, INC.)third_quarter 2026 · $2.1 million
- Oct 20, 2026LobbyingLobbying report (AVOQ, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (AVENUE SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALSTON & BIRD LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (FIERCE GOVERNMENT RELATIONS)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (CASSIDY & ASSOCIATES, INC.)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (AXADVOCACY GOVERNMENT RELATIONS)third_quarter 2026 · $0.1 million
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 6, 2026Patent
- Sep 18, 2026Trademark
- Aug 31, 2026Trademark
- Jul 1, 2026Federal awardFederal award from Department of Veterans Affairs$1,086 million
- Jul 1, 2026Federal award
- Jul 1, 2026Federal award
- Jun 5, 20268-KShareholder vote resultsItem 5.07
- Jun 1, 2026Federal award
- Jun 1, 2026Federal award
- Jun 1, 2026Federal award
- May 20, 2026Trademark
- May 6, 2026Trademark
- May 1, 2026Federal award
- May 1, 2026Federal award
- Mar 18, 2026Trademark
- Mar 2, 20268-KDirector or officer changeItem 5.02
- Mar 2, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- Feb 25, 20268-KDirector or officer changeItem 5.02
- Nov 21, 20258-KDirector or officer changeItem 5.02
- Jul 31, 20258-KDirector or officer changeItem 5.02
- Jun 4, 20258-KDirector or officer changeItem 5.02
- Jun 4, 20258-KShareholder vote resultsItem 5.07
- May 21, 20258-KDirector or officer changeItem 5.02
- May 14, 20258-KDirector or officer changeItem 5.02
- Apr 29, 20258-KDirector or officer changeItem 5.02
- Feb 27, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 28, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| McKesson Corporation MCK | $411B | $6.4B | Jun 30, 2026 |
| Cencora COR | $333B | $4.1B | Jun 30, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| Elevance Health ELV | $201B | $6.3B | Jun 30, 2026 |
| Centene Corporation CNC | $179B | $8.9B | Jun 30, 2026 |
| Humana HUM | $137B | $1.3B | Mar 31, 2026 |